Crossmark

Pharmacology and metabolism of infliximab biosimilars – A new treatment option in inflammatory bowel diseases

Crossref DOI link: https://doi.org/10.1016/j.pharep.2016.04.006

Published Print: 2016-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Włodarczyk, Marcin https://orcid.org/0000-0001-9118-4623
Fichna, Jakub

Sobolewska-Włodarczyk, Aleksandra
License Information

Text and Data Mining valid from 2016-08-01
More Information

This article is maintained by: Elsevier

Article Title: Pharmacology and metabolism of infliximab biosimilars – A new treatment option in inflammatory bowel diseases

Journal Title: Pharmacological Reports

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.pharep.2016.04.006

Content Type: article

Copyright: © 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.